Evaluation of Clinical Outcomes and Toxicities in Multiple Myeloma Patients Receiving Commercial Talquetamab

被引：0
|
作者：
Lu, Rebecca [1 ]
Chen, Jessica [1 ]
Ow, Karla [1 ]
Hildebrandt, Michelle [1 ]
Huen, Auris [1 ]
Cardoso, Richard [1 ]
Chambers, Mark [1 ]
Abreu, Michelly [1 ]
Cuellar, Elizabeth [1 ]
Ighovoyivwi, Efe [1 ]
Knight, Sarah [1 ]
Santiago, Minifrida [1 ]
Savoie, Cecilia [1 ]
Varghese, Jaimole [1 ]
Zachariah, Annie [1 ]
Becnel, Melody [1 ]
Gaballa, Mahmoud [1 ]
Orlowski, Robert [1 ]
Patel, Krina [1 ]
Pasvolsky, Oren [1 ]
Thomas, Sheeba [1 ]
Ye, Jing Christine [1 ]
Weber, Donna [1 ]
Lee, Hans [1 ]
Richards, Tiffany [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NSO-04
引用
收藏
页码：S281 / S281
页数：1
相关论文
共 50 条
  • [21] Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
    Zamanillo, Irene
    de Alba, Lucia Medina
    Gil, Rodrigo
    de la Puerta, Rosalia
    Alonso, Rafael
    Jimenez-Ubieto, Ana
    Cedena, Maria Teresa
    Calbacho, Maria
    Ayala, Rosa
    Martinez-Lopez, Joaquin
    LIFE-BASEL, 2023, 13 (09):
  • [22] Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma
    Goldman-Mazur, Sarah
    Visram, Alissa
    Rajkumar, S. Vincent
    Kapoor, Prashant
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Dingli, David
    Kourelis, Taxiarchis
    Gonsalves, Wilson I.
    Warsame, Rahma M.
    Muchtar, Eli
    Leung, Nelson
    Kyle, Robert A.
    Kumar, Shaji
    BLOOD, 2021, 138 : 3760 - +
  • [23] Clinical Outcomes of Patients with Multiple Myeloma Presenting with Renal Failure
    Vasant, Joydeep Singh
    Gupta, Naveen
    Malhotra, Hemant
    Godara, Suraj
    Yadav, Ajay
    Kumbhaj, Prashant
    Punia, Ankur
    Soni, Priyanka
    Sharma, Lalit Mohan
    SOUTH ASIAN JOURNAL OF CANCER, 2025,
  • [24] HEALTHCARE DISPARITY IN CHANGE IN CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS
    Gaur, A.
    Mishra, N.
    Kukreja, I
    Pandey, S.
    Daral, S.
    Chopra, A.
    Verma, V.
    Nayyar, A.
    Roy, A.
    Gupta, A.
    Dawar, V
    VALUE IN HEALTH, 2022, 25 (12) : S452 - S452
  • [25] Outcomes after biochemical or clinical progression in patients with multiple myeloma
    Goldman-Mazur, Sarah
    Visram, Alissa
    Kapoor, Prashant
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Dingli, David
    Kourelis, Taxiarchis
    Gonsalves, Wilson
    Warsame, Rahma
    Muchtar, Eli
    Leung, Nelson
    Binder, Moritz
    Fonder, Amie
    Hobbs, Miriam
    Hwa, Yi Lisa
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD ADVANCES, 2023, 7 (06) : 909 - 917
  • [26] Dengue Fever in Multiple Myeloma Patients: Clinical Characteristics and Outcomes
    Villefort, Humberto
    Brandao, Luciana
    Reghini, Rodrigo
    Silva, Ivan Franca e
    Schmidt Filho, Jayr
    Batista, Marjorie V.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S130 - S130
  • [27] Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience
    Feixas, Pablo Tenorio
    Cox, Catrin
    Peer, Xavier
    Cuthill, Kirsty
    Benjamin, Reuben
    Gunawan, Arief
    Cuadrado, Maria
    de Farias, Madson Correia
    Jones, John
    Shin, Jin-Sup
    Batool, Asma
    Bowcock, Stella
    Omer, Musab
    Tawde, Prachi
    Bailey, Katharine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S92
  • [28] Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
    Grajales-cruz, Ariel
    Graeter, Allison
    Hansen, Doris
    Puglianini, Omar Castaneda
    Vazquez-Martinez, Mariola
    Blue, Brandon
    Liu, Hien
    Ochoa-Bayona, Jose
    Freeman, Ciara
    Locke, Frederick
    Nishihori, Taiga
    Shain, Kenneth
    Baz, Rachid
    Alsina, Melissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S56 - S56
  • [29] Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi W.
    Russell, Jeffery
    Infante, Jeffrey
    Elsayed, Yusri
    Smit, Jennifer
    Goldberg, Jenna D.
    BLOOD ADVANCES, 2023, 7 (04) : 644 - 648
  • [30] Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
    Mancia, Stefania Stefania
    Farrell, Annamaria
    Louw, Karen
    Florendo, Erika
    Aronson, Elizabeth
    Purcell, Kiah
    Catamero, Donna D.
    Escalon, Juliet
    Thomas, Joanne
    Aponte, Annel
    Lamb, Angela
    Kirke, Diana
    Lucas, Aimee
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Richter, Joshua
    Sanchez, Larysa
    Chari, Ajai
    BLOOD, 2021, 138
12345